Cardiovascular, Obesity, Diabetes and Hypertension
PhD, Physiology and Biophysics, University of Louisville, 1990
BA, Biology, Blackburn College, 1985
The Imig laboratory is dedicated to understanding the mechanisms by which certain fatty acids “eicosanoids” influence kidney and cardiovascular function. Research in the laboratory focuses on kidney and blood vessel function in normal and disease states. We have developed novel eicosanoid-based drugs to treat diseases including hypertension, stroke, heart attacks, diabetes, and kidney diseases. These novel drugs have tremendous potential as a therapy for cardiovascular and kidney diseases.
Hypertension, Diabetes, & Metabolic Syndrome
Obesity, hypertension, and type 2 diabetes are major contributing factors to the increase in the number of patients that have cardiovascular events and end-organ damage. Metabolic syndrome is a serious health problem worldwide that has two major underlying causes, abdominal obesity and insulin resistance that clusters with other cardiovascular risk factors. Endothelial dysfunction, inflammation, oxidative stress, and insulin resistance are interrelated and increase the risk for cardiovascular events and end-organ damage in hypertension, diabetes, and metabolic syndrome. Moreover, eicosanoids are altered in these diseases and contribute to endothelial function, inflammation, oxidative stress, and insulin resistance. In particular, cyclooxygenase (COX), epoxygenase, and soluble epoxide hydrolase (sEH) metabolites are altered in disease states and contribute to the progression of disease processes. We have identified a distinct synergy between COX-2 and sEH inhibitors on the eicosanoid metabolome. This finding resulted in the development and synthesis of COX-2/sEH inhibitors that demonstrate great promise as a novel therapeutic approach for treating hypertension, diabetes, and metabolic syndrome. The goals of this project will identify novel ways to therapeutically target the eicosanoid metabolome for improving cardiovascular, renal, and pancreatic function in hypertension, diabetes, and metabolic syndrome.
Chronic Kidney Disease (CKD)
CKD from any cause is a serious public health problem; an estimated 33 million Americans have kidney disease. Hypertension, obesity, diabetes, infections, and genetic disease can lead to CKD. Other at risk groups include veterans and first-responders exposed to radiation, either on the battlefield, from terrorist events, or as a result of industrial accidents; these people risk developing radiation nephropathy and ultimately CKD. CKD also occurs in 15% of hematopoietic stem cell transplant (HSCT) patients, and has been clearly linked to irradiation at the time of the HSCT. HSCT is increasingly used worldwide for the treatment of cancer, and over 50,000 people per year now undergo HSCT. Long-term survival after HSCT is now near 50%, which means that more people will have late effects, which include CKD. CKD due to radiation also occurs after radionuclide therapy for cancer. Our laboratory has identified and developed epoxyeicosatrienoic acid (EET) analogs that show promise as a novel therapeutic approach for CKD. EET analogs have anti-inflammatory, anti-apoptotic, and anti-oxidative activities that will translate into a novel therapeutic for CKD. Consequently, we will test EET analogs as a new and better treatment for CKD.
Acute Kidney Injury (AKI)
Acute kidney injury (AKI), also known as, nephrotoxicity, occurs after exposure to drugs, other medical procedures, or exogenous toxins. The mortality rate for AKI patients is 30-60% and 20-30% of the survivors of AKI will develop CKD. There are limited options for treating AKI and these options currently include fluid and blood pressure management via drugs and intravenous fluids or hemodialysis. EETs have biological actions that implicate them as important contributors to kidney function. Over the past decade it has become increasingly apparent that EETs have a myriad of kidney actions and the overwhelming majority of these biological actions are kidney protective. Our innovation is based on the expected outcome that EET analogs have unique kidney actions that make them a novel target for developing treatments to prevent and treat AKI. Recent studies have demonstrated that EET analogs prevent AKI and renal damage that occurs with the anti-cancer drug cisplatin. This research project will identify novel ways to therapeutically target EETs for treating AKI.
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.
(Vacková Š, Kopkan L, Kikerlová S, Husková Z, Sadowski J, Kompanowska-Jezierska E, Hammock BD, Imig JD, Táborský M, Melenovský V, Červenka L.) Front Pharmacol. 2019;10:18.
(Imig JD.) Acta Physiol (Oxf). 2019 Jan;225(1):e13203.
(Imig JD.) Pharmacol Ther. 2018 Dec;192:1-19.
(Miller BS, Blumenthal SR, Shalygin A, Wright KD, Staruschenko A, Imig JD, Sorokin A.) Diabetes. 2018 11;67(11):2206-2212.
(Neckář J, Hsu A, Hye Khan MA, Gross GJ, Nithipatikom K, Cyprová M, Benák D, Hlaváčková M, Sotáková-Kašparová D, Falck JR, Sedmera D, Kolář F, Imig JD.) Am J Physiol Heart Circ Physiol. 2018 Nov 01;315(5):H1148-H1158.
(Sedláková L, Kikerlová S, Husková Z, Červenková L, Chábová VČ, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Krátký V, Červenka L, Kopkan L.) Biosci Rep. 2018 10 31;38(5).
(Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD.) Diabetologia. 2018 10;61(10):2235-2246.
(Yeboah MM, Hye Khan MA, Chesnik MA, Skibba M, Kolb LL, Imig JD.) Nephrol Dial Transplant. 2018 Aug 01;33(8):1333-1343.
Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
(Kala P, Sedláková L, Škaroupková P, Kopkan L, Vaňourková Z, Táborský M, Nishiyama A, Hwang SH, Hammock BD, Sadowski J, Melenovský V, Imig JD, Červenka L.) Physiol Res. 2018 Jul 17;67(3):401-415.
(Červenka L, Husková Z, Kopkan L, Kikerlová S, Sedláková L, Vaňourková Z, Alánová P, Kolář F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neckář J.) J Hypertens. 2018 Jun;36(6):1326-1341.
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.
(Čertíková Chábová V, Kujal P, Škaroupková P, Varňourková Z, Vacková Š, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesař V, Červenka L.) Kidney Blood Press Res. 2018;43(2):329-349.
(Campbell WB, Imig JD, Schmitz JM, Falck JR.) J Cardiovasc Pharmacol. 2017 Oct;70(4):211-224.